GLAXO.NS Cash Flow
Glaxosmithkline Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹4.84 Bn | ₹5.82 Bn | ₹12.90 Bn | ₹9.03 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹8.08 Bn | ₹0.09 Bn | ₹-0.46 Bn | ₹3.97 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹-15.43 Bn | ₹-5.61 Bn | ₹-7.69 Bn | ₹-7.37 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹-2.51 Bn | ₹0.29 Bn | ₹4.75 Bn | ₹5.63 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹2.86 Bn | ₹0.35 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from GLAXO.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).